Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,886.02 +4,017.12 (+6.82%) CMC Crypto 200
1,363.86 +86.88 (+6.80%)
ABT Jan 2025 115.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:30PM EDT. Market open.
| Previous close | 4.7500 |
| Open | 4.6200 |
| Bid | 4.5500 |
| Ask | 4.7000 |
| Strike | 115.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.6200 - 4.6200 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.54k |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.